About Us

About Us

Our business strategy is focused on targeting high-value solid oral, sterile injectable and alternative dosage form ANDAs that are difficult to develop and that bring sustainable profitability. We explore a broad range of therapeutic areas that have technically challenging drug delivery mechanisms or other niches, including products with the potential for six months of exclusivity for being first-to-file or first-to-market. Our goal is to create a broad portfolio of limited source branded and generic pharmaceutical products that will provide high-quality, affordable and accessible alternatives.